NCT06940518View on ClinicalTrials.gov

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

January 19, 2028

Study Completion Date

January 19, 2030

Conditions

IvonescimabClear Cell Renal Carcinoma

Interventions

DRUG

Ivonescimab

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Summit Therapeutics

All Listed Sponsors

collaborator

Strategic Alliance

UNKNOWN

collaborator

Summit Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER